Syndax  
Syndax制药专注于运用表观遗传学相关的方法，克服在实体瘤治疗中发生的耐药性问题。公司拥有Entinostat在全球的专利权。Entinostat是一种口服的、高选择性的组蛋白去乙酰化酶（HDAC）抑制剂，用于晚期乳腺癌和肺癌的临床治疗。同样在一组非小细胞肺癌患者的治疗中（ENCORE401），Entinostat与EGFR-TKI厄洛替尼配合使用也取得了积极有效的结果。美国国家癌症研究所（NCI）和Syndax制药就Entinostat的发展达成了合作研究和开发协议，旨在改善晚期癌症和难治性癌症的存活率。

Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer. Entinostat also demonstrated promising results in a subset of non-small cell lung cancer patients when given in combination with the EGFR-TKI erlotinib (ENCORE 401). NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement aimed at improving survival in advanced, hard-to-treat cancers.

Read more: Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer - FierceBiotech http://www.fiercebiotech.com/press-releases/syndaxs-entinostat-receives-breakthrough-therapy-designation-fda-treatment#ixzz2ejNENL8W
Subscribe at FierceBiotech